Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of SOX as the Seconde Line Chemotherapy in Advanced or Metastatic Neuroendocrine Carcinoma

NCT03279614 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT03279614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03279614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of SOX as the Seconde Line Chemotherapy in Advanced or Metastatic Neuroendocrine Carcinoma
Lead sponsor
Peking University
Phase
Phase 2
Overall status
Unknown status
Start date
September 1, 2017
Completion date
September 1, 2020
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine carcinoma